

# VAXONO

**VACCINES: PRESENT AND FUTURE  
IN ONCOLOGY**

---

**Milan (Italy)  
October 1<sup>st</sup>, 2025**

**BIANCA MARIA PALACE HOTEL**  
Viale Bianca Maria, 4

**CME Provider**



**Organizing  
Secretariat**



**UNDER THE AUSPICES OF**





## VACCINES: PRESENT AND FUTURE IN ONCOLOGY

### PRESIDENCY

#### **Paolo A. Ascierto**

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy

#### **Bernard A. Fox**

Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Institute, Portland, Oregon, US

### RATIONAL

After decades of research and clinical trials, vaccines are beginning to impact patient outcomes. While the future is bright, we still have a long way to go.

This event will be an international meeting for experts to share and discuss the latest findings and future perspectives on cancer vaccines.

The objectives of the conference are to:

- Present up-to-date data
- Interpret clinical and scientific findings and predict potential impact
- Recognize and characterize the hurdles that remain
- Provide a vision for the future if hurdles are addressed

There will be panel discussions embedded in each session to address questions raised by presentations, allow time to consider visions for the future, identify the hurdles that remain, and summarize areas of consensus and/or disagreement.

# SCIENTIFIC PROGRAM

- 08.45 am**      *Registration \*\**
- 09.00 am**      Introduction and objectives of the Meeting  
**Paolo A. Ascierto, Bernard A. Fox**
- 09.10 am**      Spectrum of cancer antigens  
**Bernard A. Fox**

## SESSION 1 – Shared Antigens

**Chairpersons: Paolo A. Ascierto, Bernard A. Fox**

- 09.30 am**      Tumor-specific antigens preferentially derive from unmutated genomic sequences  
**Claude Perreault**
- 09.50 am**      Cancer-restricted cryptic antigens are targets for T cell recognition in pancreatic cancer  
**William Freed-Pastor**
- 10.10 am**      Proteasomal-cargo vaccine, clinical activity and dark antigen T cell response  
**Rom Leidner**
- 10.30 am**      CD137 agonism enhances anti-PD1 and GVAX induced activation of expanded CD8+ T cell clones in a neoadjuvant-adjuvant resectable pancreatic cancer clinical trial  
**Eric Christenson**
- 10:50 am**      *Discussion*
- 11:15 am**      *Coffee Break \*\**

*\*\*Not Included in the CME accredited*

## SESSION 2 – Neoantigens

Chairpersons: **Paolo A. Ascierto, Bernard A. Fox**

- 11.30 am** PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematological malignancies in the adjuvant setting  
**Mesude Bicak**
- 11.50 am** Predictors of response and resistance to neoantigen vaccines in melanoma  
**Ryan Sullivan**
- 12.10 pm** Actual landscape and perspectives on Immunotherapy in Melanoma treatment  
**Paolo A. Ascierto**
- 12.30 pm** The Immune response to Neoantigen vaccine in Pancreatic Cancer  
**Martina Milighetti**
- 12.50 pm** Novel Vaccine Adjuvant based on Z Form DNA modules  
**Erwei Song**
- 01:10 pm** *Discussion*
- 01:30 pm** *Lunch \*\**

*\*\*Not Included in the CME accredited*

## SESSION 3 - Trials Presentation \*\*

Chairpersons: **Paolo A. Ascierto, Bernard A. Fox**

- 02:30 pm**      The Dark Genome is a source of promising, novel antigens for cancer immunotherapy  
**Joseph Dukes**
- 02:50 pm**      Peptide-based personalized cancer vaccine in metastatic melanoma  
**Daniela Kleine-Kohlbrecher**
- 03:10 pm**      Immune-modulatory cancer vaccines  
**Lauren Ojalvo**
- 03:30 pm**      *Discussion*
- 04:00 pm**      *Closing Remarks*
- 04:15 pm**      *Coffee Break*

## SESSION 4 - Poster Presentation \*\*

**04:30 – 05:30 pm**

***Presentation of selected posters from students/fellows worldwide***

**05.30 pm**      *CME test\*\**

*\*\*Not Included in the CME accredited*

# FACULTY

**PAOLO A. ASCIERTO**, *Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS "Fondazione G. Pascale", Naples, Italy*

**MESUDE BICAK**, *Assistant Professor, Director of Bioinformatics Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US*


**ERIC CHRISTENSON**, *Assistant Professor of Oncology, Johns Hopkins University, Baltimore, Maryland, US*

**JOSEPH DUKES**, *Chief Scientific Officer, Enara Bio Limited, Oxford, UK*

**BERNARD A. FOX**, *Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Institute, Portland, Oregon, US*

**WILLIAM FREED-PASTOR**, *Assistant Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School; Department of Medical Oncology, Division of Molecular and Cellular Oncology, Hale Center for Pancreatic Cancer Research, DFCI, Boston, Massachusetts, US; Associate Member, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, US*

**DANIELA KLEINE-KOHLBRECHER**, *Director Immuno-oncology, Evaxion Biontech, Hørsholm, Denmark*



**ROM LEIDNER**, *Director Immune Cell Experimental Therapy and Co-Director Head & Neck Cancer Programs, Providence Cancer Institute: EACRI, Portland, Oregon, US*

**MARTINA MILIGHETTI**, *Research Fellow, Memorial Sloan Kettering Cancer Center, New York, US*

**LAUREN OJALVO**, *Executive Director, Clinical Development, Oncology Moderna Therapeutics Inc., Cambridge, Massachusetts, US*

**CLAUDE PERREAULT**, *Professor, Department of Medicine, Faculty of Medicine, Université de Montréal; Principal investigator, Institut de recherche en immunologie et oncologie (IRIC), Montréal, Québec, Canada*

**ERWEI SONG**, *Professor of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China*

**RYAN SULLIVAN**, *Associate Professor, Medicine, Hematology, Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, US*

# CME - CONTINUING MEDICAL EDUCATION

ID CME 335-458160 Ed. 1

4 CME credits.

*Formative Technical Professional Objective “Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultraspecialist activity. Rare disease and gender medicine”.*

*50 participants (medical doctors, pharmacists, biologists, nurses, pediatric nurses).*

*In order to receive CME credits, participants must:*

1. attend at least 90% of the accredited CME sessions (attendance check: required signature at the beginning and at the end of works);
2. fill in the CME test (minimum 75% correct answers required);
3. fill in the evaluation form.

*Ecm certificate will be issued to successful applicants within 90 days after the end of the conference*

## **REGISTRATION**

*Registration is free of charge for medical and clinical professionals.*

*For registration, please visit: [YAX ON - Vivenko](#)*

*For information, please send an e-mail to: [eventi@vivenko.net](mailto:eventi@vivenko.net)*

## **OFFICIAL LANGUAGE**

*The official language is English.*

## CME PROVIDER

ideA-Z Project in progress S.r.l.  
Provider E.C.M. Standard n. 335  
Corso Giacomo Matteotti, 48  
20081 Abbiategrasso (MI)  
info@idea-z.it  
www.idea-z.it



## ORGANIZING SECRETARIAT

Vivenko srl Società Benefit  
Via E. De Amicis, 42 - 20123 Milano  
eventi@vivenko.net  
www.vivenko.net

